GH2616

· Suzhou Genhouse Bio Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for GH2616, covering 2024-07-08 to 2025-12-03. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor. [Phase 1]

See pricing